CRISPR-mediated CCNE1 perturbation and patient-derived endometrial xenograft models could clarify the effects of CCNE1 on tumor growth, immune infiltration, and sensitivity to CDK2 or WEE1 inhibitors. The gene discussed is CCNE1; the disease is neoplasm.